BRPI0214716B8 - kit, preparos, e uso de estrogênio e progestina na fabricação de um medicamento para uso na prevenção de gravidez - Google Patents

kit, preparos, e uso de estrogênio e progestina na fabricação de um medicamento para uso na prevenção de gravidez

Info

Publication number
BRPI0214716B8
BRPI0214716B8 BR0214716A BR0214716A BRPI0214716B8 BR PI0214716 B8 BRPI0214716 B8 BR PI0214716B8 BR 0214716 A BR0214716 A BR 0214716A BR 0214716 A BR0214716 A BR 0214716A BR PI0214716 B8 BRPI0214716 B8 BR PI0214716B8
Authority
BR
Brazil
Prior art keywords
progestin
estrogen
preparations
kit
drug
Prior art date
Application number
BR0214716A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0214716A (pt
BRPI0214716B1 (pt
Inventor
Robert G Bell
Carole Ben-Maimon
Beata Inc Iskold
Original Assignee
Teva Womens Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23313290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0214716(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Womens Health Inc filed Critical Teva Womens Health Inc
Publication of BR0214716A publication Critical patent/BR0214716A/pt
Publication of BRPI0214716B1 publication Critical patent/BRPI0214716B1/pt
Publication of BRPI0214716B8 publication Critical patent/BRPI0214716B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0214716A 2001-12-05 2002-12-04 kit, preparos, e uso de estrogênio e progestina na fabricação de um medicamento para uso na prevenção de gravidez BRPI0214716B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33580701P 2001-12-05 2001-12-05
US60/335.807 2001-12-05
PCT/US2002/038602 WO2003049744A1 (en) 2001-12-05 2002-12-04 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology

Publications (3)

Publication Number Publication Date
BR0214716A BR0214716A (pt) 2004-12-14
BRPI0214716B1 BRPI0214716B1 (pt) 2018-10-02
BRPI0214716B8 true BRPI0214716B8 (pt) 2021-05-25

Family

ID=23313290

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214716A BRPI0214716B8 (pt) 2001-12-05 2002-12-04 kit, preparos, e uso de estrogênio e progestina na fabricação de um medicamento para uso na prevenção de gravidez

Country Status (22)

Country Link
US (5) US7320969B2 (enExample)
EP (3) EP1453521B1 (enExample)
JP (3) JP2005516913A (enExample)
CN (2) CN101757628A (enExample)
AU (2) AU2002348272B2 (enExample)
BG (1) BG108736A (enExample)
BR (1) BRPI0214716B8 (enExample)
CA (2) CA2655959C (enExample)
DK (1) DK1453521T3 (enExample)
ES (2) ES2561491T3 (enExample)
FR (1) FR15C0050I2 (enExample)
HU (2) HU230759B1 (enExample)
IL (3) IL162182A0 (enExample)
LU (1) LU93156I2 (enExample)
MX (1) MXPA04005445A (enExample)
NZ (4) NZ591627A (enExample)
PL (1) PL213122B1 (enExample)
PT (1) PT1453521E (enExample)
RU (1) RU2351339C2 (enExample)
SI (1) SI1453521T1 (enExample)
WO (1) WO2003049744A1 (enExample)
ZA (1) ZA200404249B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
NZ591627A (en) * 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20090163454A1 (en) * 2003-05-02 2009-06-25 Duramed Pharmaceuticals, Inc. Methods of Step-Down Hormone Treatment
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040222123A1 (en) * 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
WO2005023657A2 (en) 2003-09-04 2005-03-17 Pharmadesign Inc. Case with pill receiving sleeves for storing and dispensing pills
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
EP1735056B1 (en) 2004-03-19 2012-10-24 Warner Chilcott Company, LLC Extended cycle multiphasic oral contraceptive method
US20050250746A1 (en) * 2004-05-06 2005-11-10 Matthew Iammatteo Premenstrual dysphoric disorder medication
MXPA06013418A (es) * 2004-05-26 2007-01-23 Wyeth Corp Composiciones y metodos para el tratamiento del trastorno disforico premenstrual.
CN101198335A (zh) * 2004-09-27 2008-06-11 潘塔希生物科学股份有限公司 雌性避孕的方法以及该用途的药盒
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
TW200626161A (en) * 2004-10-07 2006-08-01 Duramed Pharmaceuticals Inc Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20060241092A1 (en) * 2005-04-15 2006-10-26 Anderson Freedolph D Contraceptive regimens for lower-weight women
TW200726473A (en) * 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
MX2008011074A (es) * 2006-03-02 2008-09-10 Warner Chilcott Co Inc Metodo anticonceptivo oral multifasico de ciclo prolongado.
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
US9517328B2 (en) 2013-06-19 2016-12-13 Kashiv Pharma, Llc Medicament applicator
CA3037235A1 (en) 2016-09-22 2018-03-29 Alan B. Cash Method to alleviate the symptoms of pms
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US428051A (en) * 1890-05-13 Wood-working machine
US575690A (en) * 1897-01-26 Match-safe
US3568828A (en) 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US4171358A (en) 1974-04-19 1979-10-16 Eli Lilly And Company Novel contraceptive method
US4145416A (en) * 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
US4292315A (en) * 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4291014A (en) 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4438139A (en) * 1979-08-14 1984-03-20 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estrogens
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
USRE35724E (en) * 1982-04-28 1998-02-03 Bio-Technology General Corp. Contraception system and method
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4534468A (en) 1983-12-19 1985-08-13 Nuckols Walter S Calendar-oriented pill dispenser
US4736849A (en) 1983-12-19 1988-04-12 Leonard Walter G Calendar-oriented pill dispenser
JPS60174716A (ja) 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5010070A (en) 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
US5256421A (en) * 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5276022A (en) 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
JP2938463B2 (ja) * 1987-10-22 1999-08-23 マサチユセツツ・インスチチユート・オブ・テクノロジー 月経前又は後期黄体期症候群の処置
US5043331A (en) * 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5098714A (en) 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
HU9301182D0 (en) * 1990-10-25 1993-08-30 Schering Corp Method for producing fluoro-phenicole, its analogues and intermediary compounds
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (enExample) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
FR2737411B1 (fr) 1995-08-01 1997-10-17 Theramex Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
DE19531936A1 (de) 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US6139873A (en) 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
KR20000029536A (ko) * 1996-07-26 2000-05-25 이곤 이 버그 2상피임방법및프로제스틴과에스트로젠과의배합물을포함하는킷
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
AU3961697A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
WO1998004246A2 (en) 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
AU713016B2 (en) * 1996-07-26 1999-11-18 Wyeth Oral contraceptive
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19705229C2 (de) * 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
EP0968188A1 (de) * 1997-03-20 2000-01-05 Basf Aktiengesellschaft Substituierte 2-benz(o)ylpyridin derivate, deren herstellung und deren verwendung als herbizide
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
CA2301162A1 (en) 1997-09-12 1999-03-25 Michael Jay Gast Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin
US6306914B1 (en) * 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
JP2004502729A (ja) * 2000-07-06 2004-01-29 ワイス Ｓｓｒｉおよびエストロゲン剤の組み合わせ
EP1390038A2 (en) 2001-05-16 2004-02-25 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
NZ591627A (en) 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
ES2197801B1 (es) * 2002-03-05 2005-03-16 Ferrer Internacional,S.A Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
AU2003220171A1 (en) * 2002-03-11 2003-09-29 Janssen Pharmaceutica N.V. Continuous sulfatase inhibiting progestogen hormone replacement therapy
US20040142914A1 (en) * 2002-03-11 2004-07-22 Friedman Andrew Joseph Extended transdermal contraceptive regimens
EP1494679A4 (en) * 2002-04-03 2009-10-28 Barr Lab Inc STEP-BY-STEP ESTROGENTHERAPY
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040251301A1 (en) 2003-05-05 2004-12-16 Niemann Amy C. Device for calculating anticipated days for menstruation
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
WO2005023657A2 (en) 2003-09-04 2005-03-17 Pharmadesign Inc. Case with pill receiving sleeves for storing and dispensing pills
AU2004277998A1 (en) 2003-10-01 2005-04-14 Janssen Pharmaceutica N.V. Extended triphasic contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
TW200626161A (en) * 2004-10-07 2006-08-01 Duramed Pharmaceuticals Inc Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
CA2640432A1 (en) * 2006-01-27 2007-08-09 Duramed Pharmaceuticals, Inc. Regimens for treatment of conditions related to estrogen deficiency

Also Published As

Publication number Publication date
IL162182A (en) 2012-02-29
BR0214716A (pt) 2004-12-14
WO2003049744B1 (en) 2003-08-28
US20080132473A1 (en) 2008-06-05
NZ591627A (en) 2012-09-28
RU2004121155A (ru) 2005-05-27
HK1076716A1 (zh) 2006-01-27
ZA200404249B (en) 2005-08-31
SI1453521T1 (sl) 2013-11-29
CN101757628A (zh) 2010-06-30
HUP0402651A3 (en) 2009-01-28
HUP0402651A2 (hu) 2005-04-28
EP1453521B1 (en) 2013-09-04
CA2655959A1 (en) 2003-06-19
EP2305229A1 (en) 2011-04-06
NZ555299A (en) 2008-10-31
PT1453521E (pt) 2013-10-08
RU2351339C2 (ru) 2009-04-10
CN1599614A (zh) 2005-03-23
JP2012107052A (ja) 2012-06-07
NZ533242A (en) 2007-11-30
AU2002348272B2 (en) 2008-07-31
US7858605B2 (en) 2010-12-28
ES2428118T3 (es) 2013-11-06
US20030139381A1 (en) 2003-07-24
JP2005516913A (ja) 2005-06-09
DK1453521T3 (da) 2013-10-07
US7615545B2 (en) 2009-11-10
US8338396B2 (en) 2012-12-25
IL207561A0 (en) 2011-07-31
PL213122B1 (pl) 2013-01-31
US20100298279A1 (en) 2010-11-25
CA2655959C (en) 2013-05-14
BRPI0214716B1 (pt) 2018-10-02
US20080064670A1 (en) 2008-03-13
EP2305230B1 (en) 2015-11-04
US20120322777A1 (en) 2012-12-20
JP2010180236A (ja) 2010-08-19
EP2305230A1 (en) 2011-04-06
US8680084B2 (en) 2014-03-25
ES2561491T3 (es) 2016-02-26
NZ570295A (en) 2011-05-27
FR15C0050I1 (fr) 2015-08-28
FR15C0050I2 (fr) 2018-05-11
CA2468748C (en) 2010-01-26
MXPA04005445A (es) 2005-03-23
HUS1800033I1 (hu) 2018-08-28
US7320969B2 (en) 2008-01-22
AU2008237614B2 (en) 2011-04-21
EP1453521A1 (en) 2004-09-08
HU230759B1 (hu) 2018-03-28
CA2468748A1 (en) 2003-06-19
HK1154485A1 (en) 2012-04-27
BG108736A (bg) 2005-03-31
AU2008237614A1 (en) 2008-11-27
LU93156I2 (fr) 2016-09-20
CN100581550C (zh) 2010-01-20
WO2003049744A1 (en) 2003-06-19
IL162182A0 (en) 2005-11-20
PL370135A1 (en) 2005-05-16
AU2002348272A1 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
NL301115I2 (nl) Drospirenon in combinatie met estetrol
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
BR0010113B1 (pt) Preparações para uso externo na pele.
NO20032438D0 (no) Orto- og metasubstituerte bis-arylforbindelser, deres fremstilling og anvendelse samt farmasöytiske preparater inneholdende forbindelsene
NO20032187L (no) Heterocyklylalkylpiperidinderivater, deres fremstilling samt preparater inneholdende forbindelsene
ZA200402458B (en) Estrogen/gestagen combination preparation and application thereof
BR0113494B1 (pt) processo para a preparaÇço de uma formulaÇço sàlida herbicida, e, uso de uma formulaÇço sàlida herbicida.
IL155520A0 (en) Benzoxazinone derivatives, their preparation and use
UY27458A1 (es) Tetrahidroquinolinas
AU2001269252A1 (en) Alcohol-free base for aqueous perfume composition, and alcohol-free aqueous perfume composition comprising same
AR027954A1 (es) Encendedor de uso general
AU2002315737A1 (en) Sulphonated dehydrogenated sylvate, the preparation and use
CU23077A1 (es) Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
AU2001241771A1 (en) Use of avocado-soybean unsaponifiable preparations
NO20025028D0 (no) 9-oksa-epotilonderivater, fremgangsmåte for fremstilling derav samt deres anvendelse i farmasöytiske preparater
HUP0300128A3 (en) Male contraceptive composition comprising norethisterone and its use
HRP20050142A2 (en) Steroid conjugates, preparation thereof and the use thereof
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
AU2002222607A1 (en) Delivered matter forming kit with protruded case, and delivered matter with protruded case
AU2001297710A1 (en) Integrated drug development techniques
NO20026215D0 (no) Nytt hormonpreparat
AU2002236451A1 (en) Human rhinovirus assays, and compositions comprising anti-rhinoviral perturbagens
IT1318654B1 (it) Composizioni farmaceutiche comprendenti agenti antiinfiammatori e lorousi.
BR1100624A (pt) Esteróide, processo para a preparação do mesmo, composição farmacêutica, e, uso do esteróide
AU2002350460A1 (en) Estrogen/gestagen combination preparation and application thereof

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DURAMED PHARMACEUTICALS, INC. (US)

Free format text: TRANSFERIDO DE: BARR LABORATORIES, INC.

B25G Requested change of headquarter approved

Owner name: DURAMED PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080073262/SP DE 27/11/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: NOME ALTERADO DE: DURAMED PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 018110020180/SP DE 30/05/2011.

B15V Prolongation of time limit allowed

Free format text: RECONHECIDO OBSTACULO ADMINSTRATIVO E DEVOLVIDO O PRAZO DE 33 DIAS, NOS TERMOS DO ARTIGO 221 2O DA LPI E RESOLUCAO 116/2004 .

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2647 DE 28-09-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.